- OX640 is Orexo’s nasal epinephrine powder product for the acute remedy of extreme allergic reactions together with anaphylaxis, primarily based on the corporate´s proprietary drug supply platform, AmorphOX®
- The American Academy of Allergy, Bronchial asthma & Immunology (AAAAI) is the most important skilled medical group in the USA dedicated to the allergy/immunology specialty
- The AAAAI program committee chosen OX640 to be offered at its late breaking oral summary session.
Uppsala, Sweden – February 6, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), at this time proclaims the presentation of its nasal epinephrine powder product OX640 on the 2024 American Academy of Allergy, Bronchial asthma & Immunology (AAAAI) Annual Assembly. The presentation, entitled Bioavailability and Stability of an Epinephrine Nasal Powder Formulation for Therapy of Anaphylaxis, was chosen by the AAAAI program committee to be offered on the late breaking oral summary session.1, 2 Orexo’s advisor, Dr Anne Okay Ellis, Professor and Chair of the Division of Allergy & Immunology within the Division of Drugs at Queen’s College (Kingston, Ontario, CA) will give the presentation on behalf of Orexo. The AAAAI annual assembly is going down in Washington, DC, February 23-26, 2024.
OX640 is Orexo’s nasal epinephrine powder product for the acute remedy of extreme allergic reactions, together with anaphylaxis. The product is predicated on the proprietary AmorphOX drug supply platform offering fast and intensive systemic drug absorption after nasal administration in addition to glorious bodily and chemical stability. Due to its distinctive properties, OX640 has the potential to supply allergic sufferers with a needle-free, handy, and quickly appearing allergy rescue product that additionally has lengthy shelf-life and permits for versatile storage, each in cold and warm temperatures.
Dr. Ellis is a extremely esteemed knowledgeable within the discipline of allergy and has an intensive analysis file inside anaphylaxis and allergic rhinitis.
Robert Rönn, SVP and Head of R&D, mentioned: “We’re honoured that the AAAAI program committee chosen our OX640 summary to be offered at this high-profile late breaking oral summary session. This confirms the individuality with our product the place we’ve been in a position to develop a needle-free various for allergic sufferers that gives each fast onset of motion in addition to superior stability properties.”
For additional data please contact:
| Nikolaj Sørensen, President and CEO | Lena Wange, IR & Communications Director | ||
| Tel: +46 (0)18 780 88 00 | Tel: +46 (0)18 780 88 00 | ||
| E-mail: ir@orexo.com | E-mail: ir@orexo.com |
About Orexo
Orexo is a Swedish pharmaceutical firm with over 25 years of expertise creating improved prescribed drugs primarily based on proprietary formulation applied sciences that meet giant medical wants. On the US market, Orexo gives modern remedy options for sufferers affected by opioid use dysfunction and adjoining ailments. Merchandise focusing on different therapeutic areas are developed and commercialized worldwide with main companions. Whole web gross sales in 2022 amounted to SEK 624 million, and the variety of workers to 126. Orexo is listed on Nasdaq Stockholm’s fundamental listing and is on the market as an ADR on OTCQX (ORXOY) within the US.
For extra details about Orexo please go to, www.orexo.com. You can too comply with Orexo on X (former Twitter), LinkedIn, and YouTube.
About AmorphOX
Orexo’s proprietary drug supply platform, AmorphOX, is a powder made up of particles which are constructed utilizing a novel mixture of a drug, service supplies and, optionally, different components. The particles are offered as an amorphous composite of the varied components offering for glorious chemical and bodily stability, in addition to fast dissolution. The know-how works for a broad scope of energetic components and has been validated in a number of human medical research displaying fast and intensive drug publicity.
About AAAAI
AAAAI is the main membership group of greater than 7,100 allergists, bronchial asthma specialists, medical immunologists, allied well being professionals and different professionals with a particular curiosity within the analysis and remedy of allergic and immunologic ailments. Established in 1943, the AAAAI has greater than 7,100 members in the USA, Canada and 72 different international locations and is the go-to useful resource for sufferers dwelling with allergy symptoms, bronchial asthma and immune deficiency problems.
1 Journal of Allergy and Medical Immunology, Quantity 153, Challenge 2, AB367
2
